Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...

Utilizing syringe service programs to provide comprehensive PrEP care shows promise for encouraging more people who inject ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

Several health advocacy and LGBTQ organizations are urging the United States Supreme Court to uphold coverage and zero ...

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

A South African Medical Research Council (SAMRC) study has revealed that HIV remains one of the leading causes of death in ...

An end-to-end digital PrEP pathway appeared to improve accessibility, inclusivity, and service satisfaction among LGBTQ+ ...